摘要
目的探讨支气管哮喘患者诱导痰中白介素17(IL-17)、白介素8(IL-8)的水平的变化,并分析孟鲁司特钠的干预作用。方法分别选择轻度(轻度组)、中度(中度组)和重度(重度组)支气管哮喘急性发作期患者20例、18例和15例,正常对照组15例,在常规治疗的基础上,加用孟鲁司特钠片口服,检测治疗前后诱导痰IL-17和IL-8水平。结果 IL-17、IL-8水平重度组与轻度组、中度组和正常对照组比较,差异均有统计学意义(P<0.05)。经孟鲁司特治疗1个月后,诱导痰中IL-17、IL-8水平明显下降(P<0.05)。结论 IL-17及IL-8可能参与气道炎症的形成,孟鲁司特治疗哮喘的临床疗效确切。
Objective Study the change of interleukin 17 induced sputum （ IL-17）, interleukin 8 （IL-8） levels in pa- tients with bronchial asthma, and analyze the intervention effect of montelukast sodium. Methods 53 patients with acute attack of bronchial asthma were divided into three groups, the mild group（ n = 20）, the the moderate group （n = 18 ） and the severe group （n = 15 ） , 15 healthy subjects as the control group. All of patients were treated with montelukast sodium on the basis of convention- al therapy. IL-17 and IL-8 were tested before and after 1 month of treatment. Results Compared with the control group, there were statistically significant differences of IL-17 and IL-18 between the three groups（ P 〈 0.05 ） Conclusion IL-17 and IL-8 may be involved in the formation of airway inflammation of asthma. Montelukast in the treatment of clinical curative effect
出处
《四川医学》
CAS
2013年第9期1327-1329,共3页
Sichuan Medical Journal
